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To evaluate whether if ultrasonography (US)-based radiomics enables prediction of the
presence of BRAFV600E mutations among patients diagnosed as papillary thyroid carcni-
noma (PTC).
Methods
From December 2015 to May 2017, 527 patients who had been treated surgically for PTC
were included (training: 387, validation: 140). All patients had BRAFV600E mutation analysis
performed on surgical specimen. Feature extraction was performed using preoperative US
images of the 527 patients (mean size of PTC: 16.4mm±7.9, range, 10–85 mm). A Radio-
mics Score was generated by using the least absolute shrinkage and selection operator
(LASSO) regression model. Univariable/multivariable logistic regression analysis was per-
formed to evaluate the factors including Radiomics Score in predicting BRAFV600E mutation.
Subgroup analysis including conventional PTC <20-mm (n = 389) was performed (training:
280, validation: 109).
Results
Of the 527 patients diagnosed with PTC, 428 (81.2%) were positive and 99 (18.8%) were
negative for BRAFV600E mutation. In both total 527 cancers and 389 conventional PTC<20-
mm, Radiomics Score was the single factor showing significant association to the presence
of BRAFV600E mutation on multivariable analysis (all P<0.05). C-statistics for the validation
set in the total cancers and the conventional PTCs<20-mm were lower than that of the train-
ing set: 0.629 (95% CI: 0.516–0.742) to 0.718 (95% CI: 0.650–0.786), and 0.567 (95% CI:
0.434–0.699) to 0.729 (95% CI: 0.632–0.826), respectively.
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Conclusion
Radiomics features extracted from US has limited value as a non-invasive biomarker for
predicting the presence of BRAFV600E mutation status of PTC regardless of size.
Introduction
During the past decade, the incidence of thyroid cancer has rapidly increased worldwide,
regardless of the demographic groups [1–3]. The majority of thyroid cancers that are being
newly detected are papillary thyroid cancers (PTC) [4,5], a subtype consisting of more than
80% of all differentiated thyroid carcinomas [5,6]. In general, PTC is known to have excellent
patient outcomes, 5-year survival rates approaching 98–99% [7,8], but approximately 10–15%
of patients had aggressive tumor behavior, local recurrence/distant metastasis after treatment
or mortality [9–12]. At present, even with the well-known poor prognostic factors such as age
over 45 years, male gender, radioactive iodine resistance [9], it is difficult to descriminate to
predict which patient has more aggressive forms of PTCs, and effort has been made using vari-
ous biomarkers in predicting PTC patients with poor outcome.
With the advancement in molecular genetics, various genetic alterations have been revealed
and used as an adjunctive diagnostic method or for predicting patient prognosis [8,13,14].
BRAFV600E mutation, the most frequent oncogene in PTC, has been reported to be associated
with aggressive clinical features such as large tumor size, extrathyroidal extension and presence
of lymph node metastasis [8,14–16], leading to recurrence or mortality. But even with the abil-
ity of either mutation in detecting aggressive cancer types, genetic analysis requires specimen
tissue for analysis, mostly obtained from invasive surgical procedures. Aside from the informa-
tion obtained from conventional imaging, radiomics, using data extracted from medical
images converted into high-dimensional, mineable, and quantitative imaging features has
been applied to revealing tumor physiology. Other studies have linked imaging features to
molecular properties of tumors among various organs [17–20], but to the best of our knowl-
edge, no studies have applied radiomics in predicting molecular status of thyroid cancer that
can be used in predicting tumor aggressiveness. Based on this, we evaluated whether if ultraso-
nography (US)-based radiomics enables prediction of the presence of BRAFV600E mutations
among patients diagnosed as PTC.
Materials & methods
This retrospective study has been approved by the institutional review board (IRB) of Sever-
ance Hospital, Yonsei University (approval number: 4-2018-0172), with a waiver for patient
consent due to the retrospective study design. Signed informed consent was obtained from all
patients prior to biopsy or surgical procedures. Images used for data extraction were fully
anonymized before data processing according to the instructions of our IRB.
Patients
We included 527 patients who had been treated surgically with cytologically-proven or suspi-
cious thyroid cancer between December 2015 to May 2017 at Severance Hospital, Seoul,
Korea. All patients had BRAFV600E mutation analysis performed on surgical specimen. The
387 consecutive patients who had surgery from December 2015 to December 2016 were used
as the training cohort: 300 women, 87 men, mean age, 42.1 years±14.0 (range, 15–82 years).
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The 140 consecutive patients who had surgery from January 2017 to May 2017 were used as
the validation cohort: 105 women, 35 men, mean age, 41.3 years±13.4 (range, 15–74 years).
Mean age of the 527 patients were 41.9 years±13.8 (range, 15–82 years). Mean size of the thy-
roid masses was 16.4 mm±7.9 (range, 10–85 mm).
As the frequency of BRAFV600E mutation has been reported to be associated with tumor
size and conventional PTC [21], subgroup analysis was performed including thyroid cancers
confirmed as conventional PTCs measuring <20-mm (n = 389). Mean age of the 389 patients
was 42.9 years±13.1 (range, 15–80 years). Mean size of the conventional PTCs was 14.9 mm
±4.6 (range, 10–19 mm). Clinicopathologic data regarding tumor size, lymph node metastasis
were obtained from review of medical records. Imaging features of the thyroid masses used for
analysis were obtained from an institutional database.
US image selection and feature extraction
One radiologist (J.Y.K.) reviewed the preoperative US examinations of the 527 patients on the
picture archiving and communication system (PACS) and selected representative transverse
or longitudinal images of the tumor. The selected representative images were converted into
JPEG files for manual segmentation. One radiologist (J.H.Y.) who had 9 years of experience in
thyroid imaging manually set a region-of-interest (ROI) along the boundary of the selected
tumor using Paint software of Windows (Fig 1). Since ROI marking with colored brush using
Paint software alters original intensities in image, the manual ROI segmentation is conducted
over the duplicate images of collected JPEG files. Before starting ROI extracting procedure, all
images were normalized for fair comparison. First the location information of ROI marking
(coordinate information of red curves in Fig 1) was sought and then applied to the original
JPEG image to extract ROI only. This procedure ensures that the original intensity of the
Fig 1. Representative image of tumor segmentation using thyroid US. A diagonal region-of-interest (ROI) was drawn along the
tumor border (red line) for feature extraction.
https://doi.org/10.1371/journal.pone.0228968.g001
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image was not affected by the ROI extraction process. Once ROI was extracted, a total of 730
feature information were gathered. The 730 features include the first order statistics (energy,
entropy, kurtosis, skewness and so on), the second order statistics (the gray level co-occurrence
matrix (GLCM) and gray level run-length matrix (GLRLM) were established and the corre-
sponding features were extracted), and features from four discrete one-level wavelet decompo-
sitions. The detailed calculation for these features can be found in [22]. To obtain the feature
quantities, the house code in MATLAB 2018b was used. Here, 256 bins using a bin with of 1
were utilized for intensity histogram and 4 angles of 0, 45, 90, and 135 degrees were utilized
for GLCM and GLRLM anaylsis.
BRAFV600E mutational analysis
Direct DNA sequencing was used for the surgical specimen in mutation analysis. Exon 15,
which contains the BRAFV600E mutation, was amplified by PCR with the foward primer
AGGAAAGCATCTCACCTCATC and the reverse primer GATCACACCTGCCTTAAATTGC. The
PCR parameters were as follows: 94˚C for 5 minutes, 35 cycles at 94˚C for 0.5 minutes, 60˚C
for 0.5 minutes, and 72˚C for 10 minutes. The amplified products were purified with a QIA-
GEN PCR purification kit and sequenced using the foward primer described previously with
Big Dye Terminator (ABI Systems, Applied Biosystems, Foster City, CA), and an ABI PRISM
3100 Avant Genetic Analyzer (Perkin-Elmer).
Data & statistical analysis
For feature selection, LASSO logistic regression model was applied to the 730 texture features
extracted from the US images, and a Radiomics Score was calculated for each patient using a
linear combination of selected features weighted by the respective coefficients.
Univariable and multivariable logistic regression analysis was performed to calculate the
odds ratio with 95% confidence intervals (CI), including patient’s age, gender, tumor size, and
radiomics score. For internal validation, bootstrap with 1,000 resampling was used. Calibra-
tion curves were plotted to assess the calibration of the model built using the factors included,
using the Hosmer Lemeshow test. Harrell’s C-index was measured to evaluate the model’s dis-
crimination ability.
R software (version 3.4.2, http://www.R-project.org) with the R package ‘glmnet’ was used
for statistical analysis.
Results
Among the 527 patients diagnosed with PTC in this study, 428 (81.2%) were positive and 99
(18.8%) were negative for BRAFV600E mutation. Cancer subtype of the 527 masses were proven
as follows: 493 (93.5%) as conventional PTC, 23 (4.4%) as follicular variant PTC, 7 (1.3%) as
diffuse sclerosing variant PTC, 4 (0.8%) as oncocytic variant of PTC. Demographics according
to the presence of BRAFV600E mutations are summarized in Table 1. Mean tumor size was sig-
nificantly smaller in nodules positive for BRAFV600E mutation, 16.0±7.6 mm to 18.0±9.1 mm
(P = 0.003). Similar tendency was observed in the training cohort (15.8±7.4 mm to 19.6±10.0
mm, P = 0.004), but not in the validation cohort or the conventional PTC<20-mm subgroup.
Feature selection and calcuation of radiomics score
Eight potential features were selected among 730 texture features in the training cohort with
nonzero coefficients in the LASSO logistic regression model (Fig 2A and 2B). These 8 texture
features were presented in the calculation formula below used to calculate the Radiomics
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Score,
Radiomics Score ðtotalÞ ¼ 0:3715483   0:0179227 Xmad 6 0   0:0202624 X sv 43 0
  0:0000068 XHL ene 1 0   0:0000041XHL rln 48 0   0:0769504 X LL uni 13 0
  0:0013692 X LL lrlgle 54 0þ 0:0025444 X LL se 42 45þ 0:5554316 X LL se 42 90
For the conventional PTCs measuring <20-mm, 4 potential features were selected among
the 730 texture features in the training cohort (Fig 2C and 2D). These 4 texture features were
presented in the calculation formula below used to calculate the Radiomics Score
(cPTC<20-mm),
Radiomics ScoreðcPTC < 20  mmÞ ¼   2:2001791þ 11:4205518X LH srlgle 52 0   0:7666155 X LL uni 13 0
þ 0:8461400 X LL se 42 90   0:0001180 X LL lrhgle 55 90
Table 1. Demographic features of the total thyroid cancers and conventional PTCs<20-mm according to the presence of BRAFV600E mutation.
Total (n = 527)













Mean age (years) 38.4±13.2 42.7±13.8 0.284 38.3±13.4 43.1±13.9 0.009 38.8±13.1 41.7±13.4 0.288
<55 years 86 (86.9%) 334 (78.0%) 0.064 60 (87.0) 247 (77.7) 0.118 27 (87.1) 86 (78.9) 0.446
�55 years 13 (13.1%) 94 (22.0%) 9 (13.0) 71 (22.3) 4 (12.9) 23 (21.1)
Gender 0.523 0.997 0.290
Men 79 (79.8%) 326 (76.2%) 15 (22.7) 72 (22.6) 5 (16.1) 30 (27.5)
Women 20 (20.2%) 102 (23.8%) 54 (78.3) 246 (77.4) 26 (83.9) 79 (72.5)
Mean size of tumor (mm) 18.0±9.1 16.0±7.6 0.003 19.6±10.0 15.8±7.4 0.004 15.2±7.8 16.2±7.6 0.511
<20mm 67 (67.7%) 341 (79.7%) 0.015 40 (58.0) 254 (79.9) <0.001 27 (87.1) 87 (79.8) 0.511












Conventional PTC <20-mm (n = 389)









Mean age (years) 41.1±13.9 43.3±13.0 0.386 39.5±13.9 43.0±12.6 0.277
<55 years 27 (81.8) 194 (78.5) 0.837 19 (82.6) 68 (79.1) >0.999
�55 years 6 (18.2) 53 (21.5) 4 (17.4) 18 (20.9)
Gender 0.151 0.587
Men 3 (9.1) 53 (21.5) 4 (17.4) 22 (25.6)
Women 30 (90.9) 194 (78.5) 19 (82.6) 64 (74.4)
Mean size of tumor (mm) 12.9±2.7 13.0±2.3 0.843 13.1±2.0 13.3±2.4 0.720
<20mm - - -- - - -
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Development, performance, and validation of prediction models
Table 2 summarizes the results of univariable and multivariable logistic regression analysis for
predicting the presence of BRAFV600E mutations. In the training cohort of the total thyroid
cancers, tumor size and Radiomics Score were factors with statistical significance on univari-
able analysis. Among the training cohort including conventional PTCs measuring <20-mm,
Radiomics Score was the single factor showing statistical significance. In both total cancers
and the conventional PTC<20-mm, Radiomics Score was the single factor showing significant
association to the presence of BRAFV600E mutation on multivariable analysis (all P<0.05).
Fig 2. Texture feature selection using the least absolute shrinkage and selection operator (LASSO) logistic regression model.
(A) Tuning parameter (lambda, λ) selection in the LASSO model used 10-fold cross validation for 527 thyroid cancers. The mean
deviance (goodness-of-fit statistics, red dots) was plotted versus log(λ), error bars displaying the range of standard error. Dotted
vertical lines were drawn at the point of minimum deviance (λ value = 0.03229), and at the point where maximum λ was obtained
among errors smaller than the standard error of minimum deviance (λ value = 0.08984). (B) LASSO coefficient profiles of the 730
texture features. A coefficient profile was plotted versus log(λ). The gray vertical line was drawn at the value selected using 10-fold
cross validation, where the optimal λ resulted in 8 nonzero coefficients. (C) Tuning parameter (lambda, λ) selection in the LASSO
model used 10-fold cross validation for 389 conventional PTCs<20-mm. The mean deviance (goodness-of-fit statistics, red dots)
was plotted versus log(λ), error bars displaying the range of standard error. Dotted vertical lines were drawn at the point of
minimum deviance (λ value = 0.0329208), and at the point where maximum λ was obtained among errors smaller than the standard
error of minimum deviance (λ value = 0.072595). (D) LASSO coefficient profiles plotted versus log(λ), gray vertical line was drawn at
the value selected using 10-fold cross validation, where the optimal λ resulted in 4 nonzero coefficients.
https://doi.org/10.1371/journal.pone.0228968.g002
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The calibration curve of the prediction model for the presence of BRAFV600E mutation
demonstrated good agreement between prediction and observation in the training cohort
among the thyroid cancers. The Hosmer-Lemeshow test yielded statistics of P = 0.502, suggest-
ing good calibration (Fig 3A). C-statistics for the training set was 0.718 (95% CI: 0.650–0.786),
and 0.629 (95% CI: 0.516–0.742) for the validation set (Table 3). The calibration curve of
the prediction model for the presence of BRAFV600E mutation among conventional PTCs
<20-mm demonstrated good calibration, with the Hosmer-Lemeshow test yielding statistics
of P = 0.257 (Fig 3B). C-statistics for training set among the conventional PTCs<20-mm was
0.729 (95% CI: 0.632–0.826), and 0.567 (95% CI: 0.434–0.699) for the validation set.
Discussion
One major challenge for thyroid cancer is how to distinguish patients who need aggressive
treatment to survive to those who do not. There are no consistent predictors that reliably
sorts out aggressive PTCs, and in addition to the lack of prospective data regarding appropriate
treatment for PTCs due to its generally excellent survival [9], issues regarding overtreatment
for low-risk patients who will not experience PTC-related mortality have surfaced and debated
over the recent years. This reflects the need for a more effective and accurate biomarker in
predicting aggressive PTCs, including molecular analysis such as BRAFV600E mutations. Muta-
tion analysis requires invasive procedures such as biopsy or surgical resection to retrive speci-
men to be analyzed. Among the non-invasive imaging biomarkers, radiomics is an emerging
method that has the potential to predict molecular characteristics of tumors, using quantitative
imaging features extracted using data-characterization algorithms. The most widely used
imaging modality in radiomics has been computed tomography (CT) or magnetic resonance
imaging (MRI), however, US is the most sensitive and accurate imaging modality for the thy-
roid which we used in this study.
For feature selection in obtaining a Radiomics Score, the LASSO logistic regression
model was used, which enables selecting features based on their strength of association on
univariable analysis, and combining the selected features into a radiomics signature [23].
The Radiomics Score obtained was the single factor showing significant association in pre-
dicting the presence of BRAFV600E mutation in both univariable and multivariable analysis




OR 95% CI P OR 95% CI P
Tumor size 0.953 0.924–0.981 0.001 1.018 0.977–1.060 0.394
Age (�55 years) 1.916 0.948–4.308 0.089 1.948 0.928–4.536 0.096
Gender 1.054 0.573–2.035 0.871 1.757 0.877–3.793 0.129
Radiomics score 6.099 3.124–12.723 <0.001 8.979 3.603–23.920 <0.001
Conventional PTCs<20-mm
OR 95% CI P OR 95% CI P
Tumor size 1.018 0.875–1.198 0.825 1.030 0.872–1.232 0.738
Age (�55 years) 1.229 0.512–3.431 0.665 1.282 0.495–3.943 0.632
Gender 2.732 0.926–11.701 0.108 4.281 1.166–27.327 0.060
Radiomics score 9.976 3.161–38.451 <0.001 11.279 3.624–44.121 <0.001
US: ultrasonography, PTC: papillary thyroid carcinoma, OR: Odds ratio, 95% CI: 95% confidence interval
https://doi.org/10.1371/journal.pone.0228968.t002
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Fig 3. Calibration plots of the grouped prediction models for the presence of BRAFV600E mutation. For each plot,
the y-axis represents the actual probability of BRAFV600E mutation, and the x-axis represents the predicted risk for
BRAFV600E mutation. (A) Calibration plot for the total thyroid cancers and (B) conventional PTCs measuring
<20-mm included in this study.
https://doi.org/10.1371/journal.pone.0228968.g003
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in the training cohorts (Table 3), showing good discrimination for thyroid cancers with
BRAFV600E mutation in the training set (c-statistics 0.718 (95% CI: 0.650–0.786)), but with
lower c-statistics for validation set (0.629 (95% CI: 0.516–0.742). Our results show that US-
derived radiomics may have potential as a non-invasive biomarker, but currently does not
enable accurate prediction of the presence of BRAFV600E mutation in PTCs. There have been
other studies proving the potential of US-derived radiomics in predicting disease-free sur-
vival or in predicting lymph node metastasis in patients diagnosed with PTC [24,25], but to
the best of our knowledge, there are currently no studies using US radiomics features in pre-
dicting the presence of BRAFV600E mutations in patients diagnosed with thyroid cancer. Fur-
ther studies including larger number of cases are anticipated in the future to validate our
results.
Among the clinical variables, higher rates of BRAFV600E mutation was seen in thyroid
cancers of smaller size, which showed significant association on univariable analysis. As
the tumor size and subtype of thyroid cancer has been reported to have association to the
presence of BRAFV600E mutation [21], we performed a subgroup analysis using a separate
Radiomics Score calculated among the 730 texture features from a subset of 389 thyroid
cancers confirmed as conventional PTC<20-mm. When using the Radiomics Score
(cPTC<20-mm), similar results were obtained with the total 527 PTCs; Radiomics Score
(cPTC<20-mm) was the single factor showing significance on both univariable/multivari-
able analysis (all P<0.001), with c-statistics of 0.729 (95% CI: 0.632–0.826) for the training
set, lower values for the validation set, 0.567 (95% CI: 0.434–0.699). This supports that US-
radiomics has limited value in predicting BRAFV600E mutation in PTC patients, regardless
of size.
There are several limitations to this study. First, as the mutation analysis was performed
in a selected group of PTC patients, results of our study does not represent mutation features
of the general thyroid cancer population. Second, 81.2% of the PTCs in this study had
BRAFV600E mutation analysis, which may have affected our results. PTCs among our popula-
tion has been known for its high prevalence for BRAFV600E mutation [26], and results may
have differed when conducted on different populations. Last, US images were used for fea-
ture extraction in obtaining a Radiomics Score that may be used in prediction of the pres-
ence of BRAFV600E mutation. Inherent observer variability of US compared to computed
tomography (CT) or magnetic resonance imaging (MRI) may have affected our results, but
since US is currently the generally applied imaging modality for detecting and differentiat-
ing thyroid nodules, feature extraction from US images may be more appropriate in extract-
ing radiomics data among thyroid imaging. Also, ROIs for feature extraction was obtained
from one radiologist, and observer variability among different radiologists were not consid-
ered in data analysis.
In conclusion, our results show that radiomics features extracted from US has limited value
as a non-invasive biomarker for predicting the presence of BRAFV600E mutation status of PTC
regardless of size.
Table 3. Discrimination ability of the models in the total thyroid cancers and the conventional PTCs<20-mm.
Total (n = 527) Conventional PTC<20-mm (n = 389)
Original Internal validation Original Internal validation
c-statistics 95% CI Boostrapped c-statistics 95% CI c-statistics 95% CI Boostrapped c-statistics 95% CI
Training set 0.718 0.650–0.786 0.716 0.652–0.786 0.729 0.632–0.826 0.729 0.634–0.819
Validation set 0.629 0.516–0.742 0.566 0.430–0.701
https://doi.org/10.1371/journal.pone.0228968.t003
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